These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11106919)

  • 1. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ; Iglesias P; Selgas R; Bajo MA; Aguilera A
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients.
    Díez JJ; Iglesias P; Aguilera A; Bajo MA; Selgas R
    Nephrol Dial Transplant; 1999 Jul; 14(7):1704-9. PubMed ID: 10435880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL; Wallace WH; Shalet SM
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.
    Broglio F; Gottero C; Benso A; Prodam F; Casanueva FF; Dieguez C; van der Lely AJ; Deghenghi R; Arvat E; Ghigo E
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):92-8. PubMed ID: 12519418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.
    Massara F; Ghigo E; Demislis K; Tangolo D; Mazza E; Locatelli V; Müller EE; Molinatti GM; Camanni F
    Neuroendocrinology; 1986; 43(6):670-5. PubMed ID: 3093909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients.
    Cantalamessa L; Cremagnani L; Orsatti A; Vigna L; Buccianti G
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):85-9. PubMed ID: 2004477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of recombinant human erythropoietin therapy on growth hormone secretion in uremic patients undergoing peritoneal dialysis.
    Díez JJ; Iglesias P; Sastre J; Aguilera A; Bajo MA; Méndez J; Gómez Pan A; Selgas R
    Metabolism; 1999 Feb; 48(2):210-6. PubMed ID: 10024084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
    Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pyridostigmine and pirenzepine on GH responses to GHRH in hyperthyroid patients.
    Valcavi R; Dieguez C; Zini M; Page MD; Dotti C; Portioli I; Scanlon MF
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):141-4. PubMed ID: 1934529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A; Bossoni S; Bodini C; Cimino A; Pizzocolo G; Schettino M; Wehrenberg WB
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E; Arvat E; Gianotti L; Nicolosi M; Valetto MR; Avagnina S; Bellitti D; Rolla M; Müller EE; Camanni F
    Biol Psychiatry; 1994 Nov; 36(10):689-95. PubMed ID: 7880938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E; Gianotti L; Ragusa L; Valetto MR; Cappa M; Aimaretti G; Ramunni J; Grottoli S; Camanni F; Ghigo E
    Dementia; 1996; 7(5):288-92. PubMed ID: 8872421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.